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Background: Telomeres are repeated sequences (the hexanucleotide TTAGGG in vertebrates) located at chromosome
ends of eukaryotes, protecting DNA from end joining or degradation. Telomeres become shorter with each cell cycle,
but telomerase, a ribonucleoprotein complex, alleviates this attrition. The telomerase RNA component (TERC) is an
essential element of telomerase, serving as a template for telomere elongation. The H/ACA domain of TERC is
indispensable for telomere biogenesis. Mutations in the telomerase components allow accelerated telomere loss,
resulting in various disease manifestations, including bone marrow failure. To date, this is the first detailed report of an
H-box mutation in TERC that is related to human disease.
Case presentation: A 26-year-old man with myelodysplastic syndrome (MDS) had very short telomeres. Sequencing
identified a single heterozygous mutation in the H box of the patient’s TERC gene. The same mutation was also present
in his father and his son, demonstrating that it was germline in origin. The telomere length in the father’s blood was
shorter compared to age-matched healthy controls, while it was normal in the son and also in the sperm cells of the
patient. In vitro experiments suggested that the mutation was responsible for the telomere shortening in the patient’s
leukocytes and contributed to the pathogenesis of bone marrow failure in our patient.
Conclusion: We analyzed a mutation (A377G) in the H box of TERC in a young MDS patient who had significantly
short-for-age telomeres. As telomeres protect chromosomes from instability, it is highly plausible that this genetic lesion
was responsible for the patient’s hematological manifestations, including marrow failure and aneuploidy in the
hematopoietic stem cell compartment.
Keywords: Myelodysplastic syndrome (MDS), Telomerase RNA component (TERC), H/ACA box, Southern blotting,
Single Telomere Elongation Length Analysis (STELA), RNA fluorescence in situ hybridization (RNA FISH)Background
Telomeres are composed of a highly conserved repetitive
DNA sequence (TTAGGG) at the ends of eukaryotic
chromosomes with associated proteins, collectively termed
shelterin. Telomeres protect DNA from fusion with
neighboring chromosomes or degradation by exonuclease
(reviewed in [1]). In humans, telomeres are 9 – 15 kb in
length, and 100–200 base pairs of telomeric sequence are
lost in each cell replication [2]. The molecular basis of loss* Correspondence: yueda.maro@gmail.com
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unless otherwise stated.is inability to fully replicate DNA of the lagging strand
during replication (known as the end replication problem)
[3]. When telomere length is critically short, cells enter
replicative senescence or die [4]. Telomere shortening is
alleviated by enzymatic activity of telomerase, a complex
composed of telomerase reverse transcriptase (TERT),
telomerase RNA component (TERC), and other proteins
(reviewed in [1]). In most human somatic cells, telomerase
activity is suppressed; however, telomerase is active in
proliferating progenitor cells.
TERC is an RNA component transcribed by RNA
polymerase II which serves as a cognate template for
telomere synthesis. In contrast to the relatively conservedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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http://www.biomedcentral.com/1471-2350/15/68TERT, TERC’s structure, size, and sequence are divergent
among different species. Nonetheless, TERC’s secondary
structure is similar across a wide range of eukaryotes. The
human TERC gene (451 nucleotides (nt)) consists of three
major domains: the core, the CR4/CR5, and the H/ACA
scaRNA domains (Figure 1) [5]. The H/ACA scaRNA
domain has two characteristic sequences, termed the
H and ACA boxes, which resemble domains in small
nucleolar RNAs (snoRNAs). The H/ACA boxes of TERC
are essential for telomere biogenesis. H/ACA proteins,
including dyskerin, NOP10, NHP2, and GAR1, recognize
H/ACA-box sequences [6-8] and recruit TERC into a
unique subnuclear organelle called Cajal body, which is cru-
cial for assembly of telomerase components [9]. MutationshTERC
Figure 1 The secondary structure of TERC showing the
mutated nucleotide position identified in the patient. The H and
ACA boxes and the scaRNA domain are highlighted. The H box
sequences of wtTERC and mutTERC (A377G) are illustrated, with the
mutated nucleotide (A > G) shown as underlined.in the TERC gene as well as in other telomerase com-
ponents cause accelerated telomere attrition, leading
to disease: dyskeratosis congenita mainly in children
[10-15], pulmonary fibrosis [16-18], liver cirrhosis
[19], and bone marrow failure syndromes of adults
(aplastic anemia, myelodysplastic syndromes (MDS),
and others) [20-22].
Here, we report the association of an H-box mutation
of TERC with human disease in a young man with bone
marrow failure.Case presentation
Methods
Patients, DNA extraction, and sequencing
A diagnosis of MDS was based on the World Health
Organization (WHO) classification of myeloid neoplasms
[23]. Having obtained written informed consent, peripheral
blood samples were collected from our patient and his
parents at the Karolinska University Hospital. Peripheral
blood specimens of the patient’s parents were separated into
CD3-positive and -negative populations using a magnetic-
activated cell sorting (MACS) labeling system (Miltenyi
Biotec, Bergishch Gladbach, Germany), according to the
manufacturer’s protocols.
Peripheral blood samples of the patient, his father, son
and siblings were also obtained clinically at the Clinical
Genetics Laboratory, Umeå University Hospital. A sample
of the patient’s sperm cells were collected before his bone
marrow transplantation and analyzed for telomere length.
DNA was extracted from each separated cell population,
peripheral blood specimens and the sperm sample using
the QIAamp DNA Blood Mini kit or the QIAamp-96 spin
blood kits (Qiagen, Hilden, Germany). DNA integrity was
confirmed for all samples by agarose gel electrophoresis.
All exons of the TERT and TERC genes were ampli-
fied by PCR using standard conditions and analyzed
by direct sequencing using the BigDye Terminator
v3.1 Cycle Sequencing kit on a ABI 3100 DNA Sequencer
(Applied Biosystems, Grand Island, NY, USA), according
to the manufacturer’s instruction.Quantitative PCR (qPCR) analysis of telomere length
Telomere lengths of peripheral blood leukocytes in
the patient and his parents were measured by qPCR
as described by Cawthon [24,25], with several modifica-
tions [26], using the Qiagility robot and the Rotor-Gene Q
(Qiagen). Telomere lengths of peripheral blood leukocytes
in the MDS patient, his father, son and siblings, as
well as of the patient’s sperm cells were also measured by
PCR at Umeå University as described previously [27].
Data of telomere lengths were combined with refer-
ence to the telomere length of the patient’s peripheral
blood leukocytes.
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STELA was performed as previously described [28].
Briefly, PCR-amplified DNA products were resolved
by 0.7% LE agarose (Ambion, Carlsbad, CA, USA) gel
electrophoresis, followed by detection with a probe against
telomere repeats using the TeloTAGGG Telomere Length
Assay kit (Roche Applied Science, Indianapolis, IN, USA),
following the manufacturer’s protocols. For each DNA
specimen, five PCR reactions were performed in duplicate.
Plasmid construction and telomeric repeat amplification
protocol (TRAP) assay
pcDNA3 TERC was constructed by inserting TERC se-
quence into pcDNA3 plasmid (Invitrogen, Carlsbad, CA,
USA) at KpnI and EcoRI sites. A377G mutation was gener-
ated in pcDNA3 plasmid by using QuikChange Lightning
Site-Directed Mutageneis Kit (Agilent Technologies, Santa
Clara, CA, USA) according to the manufacturer’s instruc-
tions. The mutation was confirmed by Sanger sequencing.
The results of the TRAP and the RNA FISH experiments
were confirmed with two different A377G mutant clones.
Telomerase-deficient WI 38 VA13 subline 2RA cells
(VA13; ATCC, Manassas, VA, USA) were plated on
six-well culture plates (4 x 105 cells/ well) and incu-
bated for 24 hours. Either pcDNA3-wtTERC (2 μg) or
pcDNA3- mutTERC (2 μg) was cotransfected with
pcDNA3-Flag-TERT (2 μg) into the VA13 cells using
X-tremeGENE HP DNA Transfection Reagent (12 μl,
Roche Applied Science). After 48 hours, transfected
cells were washed with cold PBS, and directly lysed with
CHAPS buffer (EMD Millipore, Billerica, MA, USA) in
the wells on ice. Protein concentration was measured with
the BCA Protein Assay kit (Thermo Fisher Scientific Inc.,
Rockford, IL, USA), and telomerase activity was mea-
sured by the fluorescence-based TRAP assay using the
TRAPeze® XL Telomerase Detection kit (EMD Millipore,
Billerica, MA, USA), according to the manufacturer’s
instructions.
RNA fluorescence in situ hybridization (RNA FISH)
pcDNA3-wtTERC or pcDNA3-mutTERC was cotrans-
fected with pcDNA3-Flag-TERT into VA13 cells as de-
scribed above, and cells were subjected to RNA FISH
48 hours after transfection as described elsewhere [29,30].
As the mutation is located at nt 377 of TERC, we
used a mixture of three probes which do not overlap
the mutation site [30,31]. All probes were aminoallyl-
T-modified deoxyoligonucleotides synthesized by Integrated
DNATechnologies (Coralville, IA, USA).
Probe 1) 5′-T*GCGCGCGGGGAGCAAAAGCACGG
CGCCT*ACGCCCTTCTCAGTT*AGGGTTAGAC A-3′
(complementary to TERC nt 43–96); Probe 2) 5′- GCT*G
ACATTTTT*TGTTTGCTCT*AGAATGAACGGT*GGA
AGGCGGCAGGCCGAGGCT*T-3′(complementary toTERC nt 128–189); Probe 3) 5′-AT*GTGTGAGCCGAG
T*CCTGGGTGCACGT*CCCACAGCTCAGGGAAT*CG
CGCCGCGCT*C-3′(complementary to TERC nt 393–449).
Aminoallyl-modified thymidines are indicated by T*.
The aminoallyl-modified thymidines in the probes
were chemically conjugated with Cy3 fluorophore (Cy3
monofunctional reactive dye; Amersham Pharmacia,
Piscataway, NJ, USA), and the labeling efficiency was tested
with Nanodrop 1000 (Thermo Scientific, Wilmington, DE,
USA). Human p80-Coilin or dyskerin was detected with a
mouse monoclonal anti-Coilin antibody (1:500 dilution;
(Pdelta) ab11822, abcam, Cambridge, MA, USA) or a
rabbit polyclonal anti-dyskerin antibody (1:50 dilution;
(H-300) sc48794, Santa Cruz, Dallas, TX, USA), respect-
ively. Slides were mounted in VECTASHIELD Mounting
Medium with DAPI (Vector Laboratories, Burlingame,
CA, USA). Images were acquired by confocal laser scanning
microscopy with Zeiss LSM 780 confocal system (Carl
Zeiss MicroImaging, NY, USA) at the Light Microscopy
Core of NHLBI, NIH.
Medical history
The patient, born in 1983, was diagnosed with idiopathic
thrombocytopenic purpura (ITP) in 1994, but no clinical
follow-up was performed. In 2007, he was diagnosed
with hypoplastic MDS with platelets 25 x 109/l. Cytogenetic
analysis in 2008 showed a partial trisomy 1q with 46,XY,der
(13)t(1;13)(q11;p13) in 11 of 25 metaphase cells. In 2009,
the patient was referred to the Karolinska University
Hospital with pancytopenia showing leukocytes 2.0 x 109/l,
hemoglobin 10.0 g/dl, and platelets 20 x 109/l. Absence of
cytogenetic abnormalities and markedly reduced mar-
row cellularity on subsequent bone marrow biopsies
(in 2009 and 2010) resulted in revision of the diagnosis
from MDS to aplastic anemia (AA). The patient became
transfusion-dependent (red blood cells and platelets)
and susceptible to infection due to severe neutropenia
(leukocyte < 0.2 x 109/l). He underwent bone marrow
transplantation in 2012, but died of Epstein-Barr virus-
associated B-cell lymphoma in the same year. The patient’s
parents and two younger siblings were healthy, but
the paternal grandmother had died with bone marrow
hypoplasia at age 59. The grandmother’s sister died of
pneumonia at age 11, and her father died of pneumonia at
age 50 (Figure 2B).
Molecular analysis
DNA samples of the patient and his parents were sent to
the National Heart, Lung and Blood Institute for analysis in
2011. Since we suspected that the pedigree carried a genetic
mutation in a telomerase-associated gene, we examined
telomere content by qPCR. The telomere length of white
blood cells in the patient was extremely short as compared






































Figure 2 Familial analysis of telomere length and disease manifestations. A. The average telomere length in the patient was significantly
short compared to age-matched healthy controls. Telomere length (TL) was measured by qPCR and calculated as the telomere to single copy
gene ratio (T:S ratio). The figure illustrates the standard curve for age-related telomere length shortening in healthy donors (small open circles).
The TL of each specimen is shown as follows; the patient peripheral blood (PB), ▲; the patient’s sperm, Δ; PB of the patient’s son, ★; whole PB of
the patient’s father, ☒, CD3-negative PB of the patient’s father, ■; CD3-positive PB of the patient’s father, □; CD3-negative PB of the patient’s
mother, ●; CD3-positive PB of the patient’s mother, ○; and PB of the patient’s siblings, sister ▼and brother ◆. B. Pedigree analysis. The family
members within the shaded box were tested for the A377G TERC mutation and telomere length. The proband is indicated with an arrow. Filled
symbols represent individuals carrying the A377G mutation, whereas open symbols are individuals with no mutation. Squares; males, and circles;
females. BMF, bone marrow failure; MI, myocardial infarction; DM, diabetes mellitus; and MDS, myelodysplastic syndrome.
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length than the controls, whereas both siblings and the
patient’s son showed normal-for-age telomere content.
To further examine telomere attrition in our patient, we
employed the PCR-based technique STELA for measure-
ment of single telomere lengths in a chromosome-specific
manner. Southern blot visualization of STELA was
obtained by using telomere-specific probes (Figure 3).
Telomere lengths in 12q and especially in XpYp were
widely distributed with many short telomeres, whereas
they were less heterogeneous in 17p (Figure 3). Telomerelengths in controls were well-maintained within a defined
length range, compared to those of the patient. 17p
telomere length in controls also displayed low variation
(data not shown); 17p telomere length distributions have
been reported to be less heterogeneous compared to
other chromosomes in fibroblasts and peripheral blood
leukocytes [32].
As the patient had very short telomeres, we sequenced
all exons of the TERT and TERC genes. Only a single
heterozygous mutation at nt 377 (A377G) of TERC was
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Figure 3 STELA showed extremely short telomeres in the
patient. STELA was employed to address telomere length and
distribution in the patient in a chromosome-specific manner
(chromosomes XpYp, 12q, and 17p). A representative XpYp STELA
obtained from a healthy donor (age 38 years) is shown as a control.
Mean telomere length (TL; kb) is represented under each STELA

























Figure 4 TRAP assay showed significantly low telomerase
activity in the mutTERC (A377G). VA13 cells were co-transfected
with either pcDNA3-wtTERC or pcDNA3-mutTERC together with
pcDNA3-Flag-TERT, followed by telomerase activity measurement.
Results were calculated as a relative activity compared to values
obtained from pcDNA3-wtTERC and pcDNA3-Flag-TERT. Bars denote
standard deviations. A representative result is shown here.
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the patient’s father, both in CD3-positive and CD3-negative
populations, but not in the mother, suggesting origin
in the paternal germline. An extended family analysis
also identified the A377G mutation in the patient’s
son, whereas the patient’s two healthy siblings did not
have the mutation. A paternal influence has been reported
on telomere length of offspring [33,34], but the patient’s
son showed normal telomere length despite his A377G
mutation (Figure 2A). To clarify the inheritance of short
telomere length of the patient, we examined the telomere
length of the patient’s sperm cells: surprisingly, the
telomere length of the sperm cells was much longer
compared to the patients’ leukocytes (Figure 2A).
To address whether the TERC A377G mutation
was responsible for telomere shortening in the patient,
telomerase activity was measured by a TRAP assay, in
which pcDNA3-wtTERC or mutTERC was co-transfected
with pcDNA3-Flag-TERT into telomerase-deficient
VA13 cells. Telomerase activity was significantly reduced
(70 – 90%) in VA13 cells that had been transfected with
the mutant TERC plasmid (Figure 4).
Mutations in the H/ACA boxes of the TERC gene have
been reported to be important for TERC to assemble withH/ACA proteins including dyskerin [35]. To test the
hypothesis that the TERC A377G mutation might
cause decreased telomerase activity through impaired
interaction of TERC with H/ACA proteins or mislo-
calization of TERC in the nucleus, we performed
RNA FISH using VA13 cells transiently transfected with
pcDNA3-wtTERC /mutTERC. mutTERC did not colocalize
with Cajal body marker coilin (Figure 5A and B). Fur-
thermore, mutTERC did not colocalize with dyskerin
(Figure 5C and D).
Discussion
In this study, we have identified a mutation A377G
(AGAGGA→AGAGGG) in the H box of TERC in a
young patient with bone marrow failure. The patient
displayed short telomeres and significantly reduced
telomerase activity in vitro in the TRAP assay, suggesting
that the H box of TERC is crucial for telomere biogenesis
in humans. Analysis of the pedigree showed that the
mutation was germline. The father had no clinical
symptoms, by the age of 58, although he carried the
mutation, consistent with previous reports which have
observed variable penetrance of disease manifestations in
patients carrying TERC mutations [21,36]. The patient’s















Figure 5 mutTERC did not colocalize with dyskerin or Cajal bodies. Telomerase-defective VA13 cells were transfected with either pcDNA3-wtTERC
(A and C) or pcDNA3-mutTERC (B and D) together with pcDNA3-Flag-TERT and subjected to RNA FISH combined with immunofluorescence. wtTERC or
mutTERC was labeled with Cy3-conjugated probes (red, A-D), Cajal bodies and dyskerin were stained with anti-Coilin antibody (green, A and B) and
anti-dyskerin antibody (green, C and D), respectively. Nucleus was stained with DAPI (blue, A-D).
Ueda et al. BMC Medical Genetics 2014, 15:68 Page 6 of 8
http://www.biomedcentral.com/1471-2350/15/68symptoms and he had normal telomere length at age one
year. However, close follow-up of the boy in the future
would be necessary.
The A377G TERC mutation was previously reported
in an aplastic anemia patient, but no functional assay of the
mutation was performed [37]. The H box is extensively
conserved among snoRNAs and scaRNAs in eukaryotes,
sharing the consensus sequence “ANANNA (A: adenine,
N: any nucleotide)”. Microinjection experiments in Xenopus
oocytes have shown that all three conserved adenine
nucloetides of the H box are essential for nucleolar
localization of snoRNA U64 [38]. A human TERC mutant,
which was created by replacement of all adenines
with uracil in the conserved H box residues
(AGAGGA→UGUGGU), was undetectable in transi-
ently transfected 293 cells using polyacrylamide gel
electrophoresis [6]. Another H-box mutant (A372U) was
subjected to in vitro RNA synthesis and immunoprecipita-
tion experiments, showing severely impaired ribonucleo-
protein (RNP) formation and a critical role of the H box
for assembly of hTERC with H/ACA proteins [35]. These
studies demonstrate that integrity of the H box is essential
for hTERC stability, intracellular trafficking, and assembly
of hTERC with H/ACA proteins.
In our study, RNA FISH experiments showed that
mutTERC did not accumulate in Cajal bodies, and did not
colocalize with dyskerin. Mislocalization of mutTERCwith dyskerin is consistent with the previous report [35].
As dyskerin has been reported to be necessary for the
active telomerase enzyme complex [39], lack of association
of mutTERC with dyskerin might have caused shorter-
for-age telomere length in our patient. mutTERC did not
accumulate in Cajal bodies in the absence of CAB box
mutations. Lack of pre-RNP formation might have caused
this mislocalization. Ideally, telomerase activity should
have been tested on the patient’s samples, but these were
not available.
Of interest, telomere content of the patient’s sperm
cells was much greater compared to his leukocytes.
Sperm telomere length has been reported to correlate
with that of white blood cells in the same individual
[40], but sperm telomere length also has been reported to
increase with age [40-43]. The mechanism of elongation is
not understood, but upregulation of hTERT is suggested
to contribute [44-46]. Upregulation of hTERT might have
overcome a decrease of telomerase activity due to the
A377G TERC mutation in our patient. A decrease in
telomerase activity with telomerase mutations leads to
telomere shortening with clinical manifestations in
the hematopoietic system, but might not occur during
spermatogenesis. Disease anticipation has been reported
in TERC RNA haploinsufficiency [36,47]. Azospermia was
observed in one affected individual, suggesting that
spermatogenesis was also affected by TERC deletion [47].
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during spermatogenesis might be different depending on
mutation sites of TERC. Further analysis of individuals
with telomerase mutations is needed to examine to what
extent telomere length maintenance in sperm and bone
marrow differs.
Conclusions
The A377G mutation was identified in the H box of
TERC in a young MDS patient with a chromosomal
abnormality. As telomeres protect chromosomes from
instability, it is highly plausible that this genetic lesion
was responsible for the patient’s hematological manifes-
tations, including marrow failure and aneuploidy in the
hematopoietic stem cell compartment.
Consent
The patient and his parents provided written informed
consent for genetic testing, and publication of the re-
sults following the protocol approved by the institu-
tional review board of the National Heart, Lung, and
Blood Institute, protocol 04-H-0012 (www.ClinicalTrials.gov
identifier: NCT00071045). Analyses of peripheral blood
samples from the patient’s son and siblings were per-
formed clinically after informed consent. Sperm DNA
was analyzed after approval by the Ethical Committee at
Umeå University (#2013/157-31).
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